Optic Nerve Perfusion Following Treatment with Latanoprost Versus Brimionidin Tartrate

EARLY_PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 24, 2024

Primary Completion Date

September 1, 2024

Study Completion Date

October 1, 2024

Conditions

Glaucoma

Interventions

DRUG

Latanoprost (Xalatan)

latanoprost 0.005

DRUG

Brimonidine 0.2 %

Brimonidine0.2

Trial Locations (1)

Zagazig University, Zagazig

All Listed Sponsors

lead

Zagazig University

OTHER_GOV

NCT06730516 - Optic Nerve Perfusion Following Treatment with Latanoprost Versus Brimionidin Tartrate | Biotech Hunter | Biotech Hunter